source
- Pathos AI signs two cancer deals, including $2 bn contract with China's Alphamab and partnership with AstraZenecaPathos AI announced two new collaborations to expand its oncology pipeline, one with AstraZeneca and another with a subsidiary of China's Alphamab Oncology. The deal with Jiangsu Alphamab Biopharm…
- Pathos AI signs major ADC partnership with Chinese biotech Alphamab and targets up to $300M Series E raisePathos AI, a technology and drug development company, announced a major antibody‑drug conjugate (ADC) collaboration with Chinese biotech Alphamab. The firm also disclosed a partnership with AstraZ…